Shabir Hasham
Published on: 06/05/22
CMO and Member of the Executive Management Team
Shabir Hasham has served as Santhera’s Global Development Program Lead & Global Head Medical Affairs for the past three years, where he was responsible for overseeing the clinical development and regulatory submission of vamolorone, for the treatment of Duchenne muscular dystrophy (DMD).
“I am thrilled to be taking on the role of CMO at such a transformative point in the Company’s trajectory,” said Shabir Hasham, MD. “I look forward to helping drive Santhera’s mission in advancing vamorolone towards approval, first in the US, and later in Europe, and clinically progressing lonodelestat, whilst working with the medical communities to leverage the transformational potential of our pipeline products in and beyond DMD and cystic fibrosis, respectively.”
“I am thrilled to be taking on the role of CMO at such a transformative point in the Company’s trajectory,” said Shabir Hasham, MD. “I look forward to helping drive Santhera’s mission in advancing vamorolone towards approval, first in the US, and later in Europe, and clinically progressing lonodelestat, whilst working with the medical communities to leverage the transformational potential of our pipeline products in and beyond DMD and cystic fibrosis, respectively.”
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
